Antioxidant mitoquinone suppresses benign prostatic hyperplasia by regulating the AR–NLRP3 pathway

Mitoquinone (MitoQ), a mitochondria-targeted antioxidant, has been used to treat several diseases. The present study aimed to investigate the therapeutic effects of MitoQ in benign prostatic hyperplasia (BPH) models and their underlying molecular mechanisms. In this study, we determined that MitoQ i...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Bo-Ram, Lim, Chae-Young, Kim, Hyo-Jung, Lee, Minho, An, Hyo-Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368918/
https://www.ncbi.nlm.nih.gov/pubmed/37454529
http://dx.doi.org/10.1016/j.redox.2023.102816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368918/
https://www.ncbi.nlm.nih.gov/pubmed/37454529
http://dx.doi.org/10.1016/j.redox.2023.102816

Ejemplares similares